Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-23-022936
Filing Date
2023-06-29
Accepted
2023-06-29 16:43:45
Documents
87
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1710341
2 ex31-1.htm EX-31.1 10759
3 ex32-1.htm EX-32.1 4215
  Complete submission text file 0001493152-23-022936.txt   7206970

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE eltp-20230331.xsd EX-101.SCH 53948
5 XBRL CALCULATION FILE eltp-20230331_cal.xml EX-101.CAL 84565
6 XBRL DEFINITION FILE eltp-20230331_def.xml EX-101.DEF 200167
7 XBRL LABEL FILE eltp-20230331_lab.xml EX-101.LAB 425725
8 XBRL PRESENTATION FILE eltp-20230331_pre.xml EX-101.PRE 344007
81 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 946443
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

EIN.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 10-K | Act: 34 | File No.: 001-15697 | Film No.: 231058050
SIC: 2834 Pharmaceutical Preparations